Carbon To Carbon Unsaturation Patents (Class 514/560)
  • Patent number: 11497722
    Abstract: The present invention provides the use of a metformin salt, particularly metformin monothreonate, in the preparation of a medicament for treating cerebral infarction. The metaformin monothreonate of the present invention has an excellent effect in the treatment of cerebral infarction. The present invention also provides a method for preparing metformin monothreonate and a composition comprising metformin monothreonate.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 15, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Xuechu Zhen, Zongyin Liu, Linyi Qian, Huimin Cao
  • Patent number: 11484520
    Abstract: The present invention relates to a specialized pro-resolving lipid mediator comprising maresins, D-series resolvins, E-series resolvins, protectins or lipoxins, or a combination thereof, for use in the treatment of neurodegenerative diseases and/or autoimmune diseases.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: November 1, 2022
    Assignee: UNIVERSITAT AUTONOMA DE BARCELONA
    Inventors: Ruben Lopez Vales, Alba Sanchez Fernandez, Anna Martinez Muriana, Isaac Francos-Quijorna
  • Patent number: 11426445
    Abstract: FSP27 compositions and methods for treating cancers are described.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: August 30, 2022
    Assignee: Ohio University
    Inventors: John Kopchick, Vishwajeet Puri, Vishva Sharma, Reetobrata Basu
  • Patent number: 11266705
    Abstract: The invention concerns a nutritional or therapeutic agent comprising a molecule mix obtained from Vitis vinifera and Vaccinium angustifolium, comprising: at least 1% of catechins and epicatechins, the percentage being given by weight in relation to the total weight of the mix, preferably at least 5%, at least 5 ppm (parts per million in the mix) of ferulic acid, preferably at least 10 ppm. The invention also relates to the use of this agent due to its effects on cognitive functions in particular.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 8, 2022
    Assignees: SPECIALITES PET FOOD, ACTIV'INSIDE, INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE LAVAL
    Inventors: David Gaudout, Stephane Rey, Benoit Lemaire, Julien Bensalem, Anne Lepoudere, Delphine Lethuillier, Marie-Eve Paradis, Stephanie Dudonne, Yves Desjardins, Frederic Calon, Alexandre Dal-Pan, Charles Ramassamy
  • Patent number: 11260042
    Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: March 1, 2022
    Assignee: ABILITY PHARMACEUTICALS S.L.
    Inventors: Carles Domènech Garcia, José Alberto Alfón Coriat, Héctor Pérez Montoyo, Miguel Francisco Segura Ginard, Jose Miguel Lizcano De Vega
  • Patent number: 11219612
    Abstract: A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: January 11, 2022
    Assignee: DREMCUBED, LLC
    Inventors: Amy Motil, Matt Motil
  • Patent number: 11206775
    Abstract: A method and system for flue gas reclamation is described. In one embodiment, a flue gas reclamation system is provided. The system includes a combustion engine including an intake member, an output shaft, and an exhaust outlet. The intake member receives flue gas from a gas source. A generator is connected to the output shaft and a compressor is connected to the exhaust outlet of the combustion engine. At least one holding tank is connected to the compressor and the compressor stores enriched flue gas from the exhaust outlet of the combustion engine in the at least one holding tank. A battery is connected to the generator and is configured to provide electric power to the flue gas reclamation system. An algae farm in fluid communication with the at least one holding tank is configured to receive the stored enriched flue gas from the at least one holding tank.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: December 28, 2021
    Assignee: Honda Motor Co., Ltd.
    Inventors: Daniel T. Sellars, Joel W. Agner
  • Patent number: 11197840
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of mental illness involving administration of 10-HDA. More particularly, methods are taught herein for the treatment and/or prophylaxis of obsessive compulsive disorder, anxiety disorder or a condition characterised by one or more symptoms of a obsessive compulsive disorder or an anxiety disorder.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 14, 2021
    Inventors: Wah Chin Boon, Steve Cheung
  • Patent number: 11197490
    Abstract: Preservation of newly-extracted roe sacks of sturgeons for subsequent harvesting of roe and caviar production, wherein said preservation employs an oil derived from roe sack membrane normally discarded in conventional caviar production. Such preservation enables roe sacks with retained roe derived from farmed or wild sturgeon to be stored and transported whereby export can be considered. The same oil, or fatty acid-containing fractions thereof, may also find use in dietary compositions, e.g. pet foods.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: December 14, 2021
    Assignee: Shah Caviar Limited
    Inventors: Kenneth Benning, Jemima Benning
  • Patent number: 11191293
    Abstract: A synthetic nutritional composition comprising a fatty acid derivative for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: December 7, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Nora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai
  • Patent number: 11143660
    Abstract: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 12, 2021
    Assignee: Hills Pet Nutrition, Inc.
    Inventor: Nolan Frantz
  • Patent number: 11097035
    Abstract: Disclosed herein is the correlation of chemical properties of oils with the physical properties of a resulting cured oil composition. Also disclosed are biocompatible materials and coatings for medical devices prepared using enriched oils and methods for enhancing or modifying the physical and chemical characteristics of cured oils by enriching such oils with fatty acid alkyl esters. Methods of tailoring the properties of biocompatible materials and coatings to deliver one or more therapeutic agents are also provided.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: August 24, 2021
    Assignee: ATRIUM MEDICAL CORPORATION
    Inventors: Keith M. Faucher, Theresa K. Albergo, Paul Martakos
  • Patent number: 11083782
    Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 10, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Sathy Balu-Iyer, Richard Bankert, Radha Ramakrishnan, Robert Dingman, Vandana Iyer, Jennifer Schneider, Fiona Yau Glassman, Nhan Hanh Nguyen
  • Patent number: 11077070
    Abstract: The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 3, 2021
    Assignee: Wilmore Labs LLC
    Inventor: Otis L. Blanchard
  • Patent number: 11065220
    Abstract: Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: July 20, 2021
    Assignee: Wintermute Biomedical, Inc.
    Inventors: Weston J. Hale, Thomas F. Rau
  • Patent number: 11044913
    Abstract: The present disclosure provides silylated polyalcohols, compositions thereof and their use as medical, insecticidal, prophylactic or therapeutic substances for the treatment or prevention of infection or infestation by arthropods. More specifically, the disclosure relates to the methods of treatment of infections or infestation by lice in a human comprising administration of an effective amount of silylated polyalcohols and compositions thereof.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 29, 2021
    Assignee: Oystershell NV
    Inventor: Bart Rossel
  • Patent number: 11032021
    Abstract: The invention relates to the use of a very low dosage form of abscisic acid (ABA) or an in vivo hydrolysable conjugate thereof, preferably ABA-glucosyl ester (ABA-GE), for nutracentic/therapeutic use for controlling and/or preventing hyperglycaemia and weight gain in response to sugar intake with a reduction in insulin secret and an increase in muscle performance.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 8, 2021
    Assignee: NUTRAVIS S.R.L.
    Inventors: Elena Zocchi, Mirko Magnone, Umberto Benatti, Giovanni Del Re, Antonio De Flora
  • Patent number: 11026916
    Abstract: Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: June 8, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Szabolcs Peter, Joseph Schwager
  • Patent number: 11013681
    Abstract: Cosmetic composition for healing and treating the skin, the formula of which consists exclusively of compounds functional for the skin and/or compounds functional both for the skin and also for the structure of the formula.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: May 25, 2021
    Assignee: BAKEL SRL
    Inventor: Raffaella Gregoris
  • Patent number: 10993663
    Abstract: The invention provides a neck-worn sensor that is a single, body-worn system that measures the following parameters from an ambulatory patient: heart rate, pulse rate, pulse oximetry, respiratory rate, temperature, thoracic fluid levels, stroke volume, cardiac output, and a parameter sensitive to blood pressure called pulse transit time. From stroke volume, a first algorithm employing a linear model can estimate the patient's pulse pressure. And from pulse pressure and pulse transit time, a second algorithm, also employing a linear algorithm, can estimate systolic blood pressure and diastolic blood pressure. Thus, the sensor can measure all five vital signs along with hemodynamic parameters. It also includes a motion-detecting accelerometer, from which it can determine motion-related parameters such as posture, degree of motion, activity level, respiratory-induced heaving of the chest, and falls.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: May 4, 2021
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
    Inventors: Matthew Banet, Kenneth Robert Hunt, Marshal Singh Dhillon, Susan Meeks Pede
  • Patent number: 10933043
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Deakin University, The Fiorey Institute of Neuroscience and Mental Health
    Inventors: Steve Cheung, Wah Chin Boon
  • Patent number: 10934389
    Abstract: The present disclosure relates to synthesis of porous polymer networks and applications of such materials. The present disclosure relates to a method of fabricating of a porous polymer network comprising: (a) providing: (i) a first reactant comprising a plurality of compounds comprising at least one acetyl group, said plurality of compounds comprising at least one compound type, and (ii) a second reactant comprising an alkylsulfonic acid, and (b) creating a solution of said reactants, (c) casting said solution in a form, and (d) treating said solution under such conditions so as to produce a porous polymer network.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: March 2, 2021
    Assignee: The Texas A&M University System
    Inventors: Lei Fang, Zi-Hao Guo, Chenxu Wang, Qiang Zhang, Hong-Cai Zhou
  • Patent number: 10905724
    Abstract: A method for decreasing proliferation of cancer cells comprises the steps of administering a sensitizer. Sensitizers can include selenium, fish oil, and a combination of selenium and fish oil to a cancer cell. The method contemplates that the selenium and fish oil are administered in an amount effective to respectively increase the sensitivity of the cancer cells, and the administration of the combination of selenium and fish oil are administered in an amount effective to synergistically increase the sensitivity of the cancer cells more than the selenium or the fish oil alone. The method additionally exposes cancer cells to temperatures in excess of 37° C.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: February 2, 2021
    Inventor: Houn Simon Hsia
  • Patent number: 10898454
    Abstract: A composition for the prophylaxis and/or treatment of a developmental disorder which is associated with preterm birth, and a method for the diagnosis and/or determination and/or prediction of the degree of severity of a developmental disorder which is associated with preterm birth.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 26, 2021
    Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET
    Inventors: Wolfgang Bernhard, Axel Franz
  • Patent number: 10894027
    Abstract: Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: January 19, 2021
    Assignee: Micelle BioPharma, Inc.
    Inventors: Frederick D. Sancilio, Thorsteinn Thorsteinsson, Glynis Daniel-Archibald, Miguel Lopez-Toledano, Ahmed Abd Almalik Ahmed Mohammed Daak
  • Patent number: 10888539
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 10869850
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: December 22, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10864185
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 15, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10849870
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 1, 2020
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Patent number: 10813903
    Abstract: The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: October 27, 2020
    Assignee: Afimmune Limited
    Inventors: Jonathan Rowe, Kevin Duffy, John Climax
  • Patent number: 10808050
    Abstract: An antibody-drug conjugate having a cyclic benzylidene acetal linker represented by formula (1) or formula (2), wherein Y is an antibody; D is a drug; R1 and R6 are each independently a hydrogen atom or a hydrocarbon group; R2, R3, R4 and R5 are each independently an electron-withdrawing or electron-donating substituent or a hydrogen atom; s is 1 or 2, t is 0 or 1, and s+t is 1 or 2; w is an integer of 1 to 20; and Z1 and Z2 are each independently a selected divalent spacer:
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: October 20, 2020
    Assignee: NOF CORPORATION
    Inventors: Takuma Tsubusaki, Yuji Yamamoto
  • Patent number: 10758508
    Abstract: Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (the pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 1, 2020
    Inventor: Seth Feuerstein
  • Patent number: 10744107
    Abstract: There is provided herein a method of treating a poikilothermic organism, such as marine bivalves, in a decreasing temperature environment which method comprises exposing the organism to a source of eicosapentaenoic acid (EPA) at temperatures of from 18° C. to about 12° C., and then exposing the organism to a source of docosahexaenoic acid (DHA) at temperatures of from about 11° C. to about 5° C. There is also provided herein a method of just conducting the first or second exposing step without the other, and also a method of using a decrease in temperature to catalyze the organism to produce EPA and/or DHA and/or non-methylene-interrupted fatty acids (NMIs).
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: August 18, 2020
    Inventor: Sixto E. Portilla
  • Patent number: 10729637
    Abstract: The present disclosure relates to compositions suitable as leave-in hairstyling compositions comprising (a) a first polysaccharide comprising inulin; (b) a second polysaccharide comprising carrageenan; (c) a third polysaccharide; and (d) a humectant. The compositions as leave-on hair styling do not require synthetic film-forming polymers nor do they require silicones. The leave-on hair styling compositions are particularly useful in methods for imparting durable styling or shaping benefits to hair.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 4, 2020
    Assignee: L'OREAL
    Inventors: Sana Ghani, Aziza Khader Suleiman, Vanessa Decarlo
  • Patent number: 10682397
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 16, 2020
    Assignees: Massachusetts Institute of Technology, Duke University
    Inventors: Benjamin David Auerbach, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Patent number: 10668041
    Abstract: The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 2, 2020
    Assignee: Societe des Produits Nestle SA
    Inventors: Yuanlong Pan, Brian Michael Zanghi, Jean-Christophe Bouthegourd
  • Patent number: 10653703
    Abstract: The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 19, 2020
    Assignee: Solutex NA LLC
    Inventors: Charles Nicholas Serhan, Fernando Moreno Egea, Joan Clària Enrich
  • Patent number: 10633324
    Abstract: This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 28, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nicolas G. Bazan, Nicos A. Petasis
  • Patent number: 10576053
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 3, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10576051
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 3, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10537543
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 21, 2020
    Assignee: DS Biopharma Limited
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Patent number: 10485784
    Abstract: An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 26, 2019
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Carmelita Frondoza, Todd R. Henderson, Reinhard Grzanna
  • Patent number: 10485779
    Abstract: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 26, 2019
    Assignee: Calanus AS
    Inventors: Jan Raa, Gunnar Rorstad, Kurt Steinar Tande
  • Patent number: 10449172
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 22, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10350186
    Abstract: The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Mark Puder, Kathleen M. Gura
  • Patent number: 10265290
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: April 23, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 10258588
    Abstract: The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (CR) compounds, wherein the lipids are cell-free and the CR compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair. Also, the invention pertains to a method for the therapeutic or cosmetic treatment of a mammal comprising the administration of the composition of the invention and preferably injecting the composition while withdrawing the injection needle until the tissue area of interest is treated.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: April 16, 2019
    Assignee: PB&B SA
    Inventors: Anthony Youri Aho, Raghunathan Sandeep
  • Patent number: 10258589
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 16, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10258587
    Abstract: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes over 25 wt % of the one or more branched chain fatty acid.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 16, 2019
    Assignee: Cornell University
    Inventors: James Thomas Brenna, Rinat Ran-Ressler
  • Patent number: 10251856
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 9, 2019
    Assignees: DEAKIN UNIVERSITY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
    Inventors: Steve Cheung, Wah Chin Boon